Essex Announces Release and Conference Call Dates for Its First Quarter 2026 Earnings
Get Alerts ESS Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 3.5%
EPS Growth %: -57.8%
Join SI Premium – FREE
SAN MATEO, Calif.--(BUSINESS WIRE)-- Essex Property Trust, Inc. (NYSE: ESS) announced today that it plans to release its first quarter 2026 earnings after the market closes on Tuesday, April 28, 2026. A conference call with senior management is scheduled for Wednesday, April 29, 2026 at 10:00 a.m. Pacific Time or 1:00 p.m. Eastern Time.
The first quarter conference call is open to everyone and can be accessed by:
Internet: Go to www.essex.com; click on Investors and the first quarter earnings webcast.
Phone: Dial toll-free, (877) 407-0784, or toll/international, (201) 689-8560. No passcode is necessary.
Replay: A rebroadcast of the live call will be available online for 30 days and digitally for 7 days. To access the replay online, go to www.essex.com and select Investors and the first quarter earnings webcast. To access the replay digitally, dial (844) 512-2921 using the Replay Pin Number – 13759660.
About Essex Property Trust, Inc.
Essex Property Trust, Inc., an S&P 500 company, is a fully integrated real estate investment trust (“REIT”) that acquires, develops, redevelops, and manages multifamily residential properties in selected West Coast markets. Essex currently has ownership interests in 259 apartment communities comprising over 63,000 apartment homes with an additional property in active development. Additional information about the Company can be found on the Company’s website at www.essex.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260407617717/en/
Contact Information
Loren Rainey
Sr. Director, Investor Relations
(650) 655-7800
[email protected]
Source: Essex Property Trust, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Iberdrola selects ICEYE to strengthen its network in the face of extreme weather
- Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share